Allison Dorval
CIK 1625110 · Chief Financial Officer · last filed 2025-07-28
Allison Dorval is a Chief Financial Officer who has filed 33 SEC Form 4 insider transactions across 5 companies since 2014. The most recent filing, for VERV, was dated Jul 28, 2025. Across all open-market trades the lifetime net is −$237.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.54M
5
33
-$237.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Verve Therapeutics, Inc. (VERV) Delisted | Chief Financial Officer | 0 | $11.13 | $0 | -$35.6K | 10 | 2025-07-28 |
| PBYI | Director | 75,390 | $7.33 | $552.6K | -$111.1K | 7 | 2025-06-17 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | — | $93.80 | — | $0 | 4 | 2024-06-07 |
| VYGR | Chief Financial Officer | 109,894 | $3.50 | $384.6K | -$91.2K | 8 | 2021-03-23 |
| PODD | Chief Financial Officer | 37,415 | $149.70 | $5.60M | $0 | 4 | 2015-04-03 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-28 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | −13,280 | $0 | EDGAR |
| 2025-06-17 | PBYI | Sell (S) | −11,610 | -$39.5K | EDGAR |
| 2025-06-13 | PBYI | Grant (A) | +27,000 | $0 | EDGAR |
| 2025-04-03 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | +7,900 | -$13.9K | EDGAR |
| 2025-01-10 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-12-03 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | +1,320 | -$3.1K | EDGAR |
| 2024-06-21 | PBYI | Grant (A) | +27,000 | $0 | EDGAR |
| 2024-06-17 | PBYI | Sell (S) | −11,000 | -$37.1K | EDGAR |
| 2024-06-07 | Jade Biosciences, Inc. (AVTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-16 | Verve Therapeutics, Inc. (VERV) Delisted | Grant (A) | — | $0 | EDGAR |